To ascertain if hydroxychloroquine (HCQ)/chloroquine (CLQ) and other conventional disease-modifying anti-rheumatic drugs (cDMARDs) use, and rheumatic diseases per se, may be associated with COVID-19-related risk of hospitalization and mortality.
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy / Alegiani, S.S., Crisafulli, S., Rossi, P.G., Mancuso, P., Salvarani, C., Atzeni, F., Gini, R., Kirchmayer, U., Belleudi, V., Kurotschka, P.K., Leoni, O., Ludergnani, M., Ferroni, E., Baracco, S., Massari, M., Trifirò, G.. - In: RHEUMATOLOGY. - ISSN 1462-0324. - 60:Spec. Iss.(2021), pp. SI25-SI36. [10.1093/rheumatology/keab348]
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy
Salvarani, Carlo;
2021
Abstract
To ascertain if hydroxychloroquine (HCQ)/chloroquine (CLQ) and other conventional disease-modifying anti-rheumatic drugs (cDMARDs) use, and rheumatic diseases per se, may be associated with COVID-19-related risk of hospitalization and mortality.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
